{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:54:45Z","timestamp":1790268885234,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","seminarsinnephrology.org","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.semnephrol.2018.01.006","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T22:13:33Z","timestamp":1522188813000},"page":"175-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Metabolomics and Metabolic Reprogramming in Kidney Cancer"],"prefix":"10.1016","volume":"38","author":[{"given":"Robert H.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2018.01.006_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/sj.ki.5000065","article-title":"Kidney cancer: identification of novel targets for therapy","volume":"69","author":"Weiss","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib3","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1681\/ASN.2015121335","article-title":"The nephrologist's tumor: basic biology and management of renal cell carcinoma","volume":"27","author":"Hu","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrneph.2017.59","article-title":"Metabolic reprogramming in clear cell renal cell carcinoma","volume":"13","author":"Wettersten","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib5","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1158\/2159-8290.CD-12-0345","article-title":"Cancer cell metabolism: one hallmark, many faces","volume":"2","author":"Cantor","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40170-016-0154-8","article-title":"Novel drugs that target the metabolic reprogramming in renal cell cancer","volume":"4","author":"van der Mijn","year":"2016","journal-title":"Cancer Metab"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.urolonc.2011.05.013","article-title":"Urine metabolomics for kidney cancer detection and biomarker discovery","volume":"29","author":"Ganti","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrneph.2011.152","article-title":"Metabolomics in the study of kidney diseases","volume":"8","author":"Weiss","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib10","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/494416a","article-title":"Big biology: the 'omes puzzle","volume":"494","author":"Baker","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib11","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1158\/0008-5472.CAN-14-1703","article-title":"Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis","volume":"75","author":"Wettersten","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2015.12.004","article-title":"An integrated metabolic atlas of clear cell renal cell carcinoma","volume":"29","author":"Hakimi","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature10602","article-title":"Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia","volume":"481","author":"Metallo","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nature10642","article-title":"Reductive carboxylation supports growth in tumour cells with defective mitochondria","volume":"481","author":"Mullen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib15","doi-asserted-by":"crossref","first-page":"6746","DOI":"10.1158\/0008-5472.CAN-17-0930","article-title":"Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging","volume":"77","author":"Abu Aboud","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0969-8051(00)00141-4","article-title":"Quantitative assessment of tumor metabolism using FDG-PET imaging","volume":"27","author":"Weber","year":"2000","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib17","first-page":"1059","article-title":"Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials","volume":"47","author":"Shankar","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/bjc.2011.579","article-title":"Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?","volume":"106","author":"Tunariu","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra050276","article-title":"Positron-emission tomography and assessment of cancer therapy","volume":"354","author":"Juweid","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib20","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1593\/neo.07724","article-title":"Regulation of the Warburg effect in early-passage breast cancer cells","volume":"10","author":"Robey","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib21","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.juro.2016.02.2992","article-title":"Diagnostic challenges in kidney cancer: a systematic review of the role of PET\/CT","volume":"196","author":"Gofrit","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1476-4598-5-64","article-title":"Pathway analysis of kidney cancer using proteomics and metabolic profiling","volume":"5","author":"Perroud","year":"2006","journal-title":"Mol Cancer"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1074\/mcp.M800252-MCP200","article-title":"Grade-dependent proteomics characterization of kidney cancer","volume":"8","author":"Perroud","year":"2008","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","article-title":"A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors","volume":"71","author":"Raez","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.bbabio.2009.03.003","article-title":"Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate","volume":"1787","author":"Chen","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib27","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02293980. 2017."},{"key":"10.1016\/j.semnephrol.2018.01.006_bib28","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1158\/0008-5472.CAN-11-3105","article-title":"Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis","volume":"72","author":"Ganti","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib29","doi-asserted-by":"crossref","first-page":"e71115","DOI":"10.1371\/journal.pone.0071115","article-title":"Inhibition of PPAR-alpha induces cell cycle arrest and apoptosis and synergizes with glycolysis inhibition in kidney cancer cells","volume":"8","author":"Abu Aboud","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib30","doi-asserted-by":"crossref","first-page":"C890","DOI":"10.1152\/ajpcell.00322.2014","article-title":"PPARalpha inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth","volume":"308","author":"Abu","year":"2015","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib31","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.juro.2008.04.135","article-title":"Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma","volume":"180","author":"Horiguchi","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib32","first-page":"213","article-title":"Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts","volume":"60","author":"Pizer","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib33","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.juro.2008.03.186","article-title":"Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells","volume":"180","author":"Horiguchi","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib34","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1016\/S0021-9258(17)30447-7","article-title":"Indoleamine 2,3-dioxygenase. Purification and some properties","volume":"253","author":"Shimizu","year":"1978","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib35","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/sj.cdd.4401073","article-title":"T cell apoptosis by tryptophan catabolism","volume":"9","author":"Fallarino","year":"2002","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib36","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1365-2567.2002.01526.x","article-title":"Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division","volume":"107","author":"Lee","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib37","doi-asserted-by":"crossref","first-page":"66540","DOI":"10.18632\/oncotarget.11658","article-title":"Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer","volume":"7","author":"Trott","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib38","doi-asserted-by":"crossref","first-page":"37762","DOI":"10.18632\/oncotarget.9326","article-title":"The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells","volume":"7","author":"Jochems","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib39","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.cmet.2013.02.002","article-title":"In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation","volume":"17","author":"Gameiro","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib40","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","article-title":"Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib41","first-page":"34","article-title":"Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC)","author":"Meric-Bernstam","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib42","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1158\/1535-7163.MCT-16-0197","article-title":"Dual and specific inhibition of NAMPT and PAK4 by KPT-9274 decreases kidney cancer growth","volume":"15","author":"Abu Aboud","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib43","first-page":"8","article-title":"Argininosuccinate synthase: at the center of arginine metabolism","volume":"2","author":"Haines","year":"2011","journal-title":"Int J Biochem Mol Biol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib44","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/ijc.22322","article-title":"Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase","volume":"120","author":"Yoon","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib45","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nature15529","article-title":"Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis","volume":"527","author":"Rabinovich","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib46","first-page":"11","article-title":"Arginine deprivation therapy for malignant melanoma","volume":"5","author":"Yoon","year":"2013","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nature21112","article-title":"Cancer genomics: spot the difference","volume":"541","author":"Peyser","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib48","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1535-6108(03)00331-3","article-title":"Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN","volume":"5","author":"Sumitomo","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib50","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.juro.2014.03.097","article-title":"Prognostic significance of biallelic loss of PTEN in clear cell renal cell carcinoma","volume":"192","author":"Lee","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib51","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib52","first-page":"1201","article-title":"Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features","volume":"149","author":"Bjornsson","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib53","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1158\/0008-5472.CAN-03-2904","article-title":"Akt stimulates aerobic glycolysis in cancer cells","volume":"64","author":"Elstrom","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib54","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.cdd.4402285","article-title":"Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II","volume":"15","author":"Miyamoto","year":"2008","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib55","doi-asserted-by":"crossref","first-page":"34495","DOI":"10.1074\/jbc.C800170200","article-title":"Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2","volume":"283","author":"Toschi","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib56","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1586\/14737140.7.6.863","article-title":"Targeting the PI3K-Akt pathway in kidney cancer","volume":"7","author":"Park","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib57","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/35017054","article-title":"Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein","volume":"2","author":"Ohh","year":"2000","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib58","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-07-4921","article-title":"Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors","volume":"14","author":"Nickerson","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib59","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1158\/0008-5472.CAN-03-0846","article-title":"The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression","volume":"64","author":"Schwartzenberg-Bar-Yoseph","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cell.2006.05.036","article-title":"TIGAR, a p53-inducible regulator of glycolysis and apoptosis","volume":"126","author":"Bensaad","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib61","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1073\/pnas.1002459107","article-title":"Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species","volume":"107","author":"Suzuki","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib62","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1158\/0008-5472.CAN-03-1541","article-title":"p53 pathway in renal cell carcinoma is repressed by a dominant mechanism","volume":"64","author":"Gurova","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib63","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1073\/pnas.0308061100","article-title":"The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress","volume":"101","author":"Shaw","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib64","doi-asserted-by":"crossref","first-page":"12361","DOI":"10.1007\/s13277-014-2550-4","article-title":"Novel mutations and role of the LKB1 gene as a tumor suppressor in renal cell carcinoma","volume":"35","author":"Yalniz","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib65","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/bjc.2012.574","article-title":"Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo","volume":"108","author":"Duivenvoorden","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib66","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1073\/pnas.94.13.6658","article-title":"c-Myc transactivation of LDH-A: implications for tumor metabolism and growth","volume":"94","author":"Shim","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib67","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1128\/MCB.00440-07","article-title":"Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1","volume":"27","author":"Kim","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib68","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature07823","article-title":"c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism","volume":"458","author":"Gao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib69","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1073\/pnas.1507228112","article-title":"MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism","volume":"112","author":"Shroff","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib70","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ccr.2008.10.016","article-title":"HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma","volume":"14","author":"Gordan","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semnephrol.2018.01.006_bib71","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3233\/KCA-170014","article-title":"Translating metabolic reprogramming into new targets for kidney cancer","volume":"1","author":"Abu Aboud","year":"2017","journal-title":"Kidney Cancer"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929518300068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929518300068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T04:11:33Z","timestamp":1660709493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929518300068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0270929518300068"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.01.006","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolomics and Metabolic Reprogramming in Kidney Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}